- Home
- CRNT vs DSGN Comparison
CRNT vs DSGN Comparison
Compare CRNT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNT
- DSGN
- Stock Information
- Founded
- CRNT 1996
- DSGN 2017
- Country
- CRNT Israel
- DSGN United States
- Employees
- CRNT N/A
- DSGN N/A
- Industry
- CRNT Radio And Television Broadcasting And Communications Equipment
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- CRNT Technology
- DSGN Health Care
- Exchange
- CRNT Nasdaq
- DSGN Nasdaq
- Market Cap
- CRNT 218.8M
- DSGN 208.9M
- IPO Year
- CRNT 2000
- DSGN 2021
- Fundamental
- Price
- CRNT $2.45
- DSGN $4.00
- Analyst Decision
- CRNT Strong Buy
- DSGN Hold
- Analyst Count
- CRNT 5
- DSGN 1
- Target Price
- CRNT $5.85
- DSGN $4.00
- AVG Volume (30 Days)
- CRNT 728.3K
- DSGN 101.9K
- Earning Date
- CRNT 08-06-2025
- DSGN 08-04-2025
- Dividend Yield
- CRNT N/A
- DSGN N/A
- EPS Growth
- CRNT 367.84
- DSGN N/A
- EPS
- CRNT 0.25
- DSGN N/A
- Revenue
- CRNT $394,344,000.00
- DSGN N/A
- Revenue This Year
- CRNT $3.12
- DSGN N/A
- Revenue Next Year
- CRNT $7.89
- DSGN N/A
- P/E Ratio
- CRNT $9.86
- DSGN N/A
- Revenue Growth
- CRNT 11.94
- DSGN N/A
- 52 Week Low
- CRNT $1.95
- DSGN $2.60
- 52 Week High
- CRNT $5.73
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- CRNT 59.42
- DSGN 55.03
- Support Level
- CRNT $2.53
- DSGN $3.52
- Resistance Level
- CRNT $2.49
- DSGN $4.21
- Average True Range (ATR)
- CRNT 0.10
- DSGN 0.28
- MACD
- CRNT 0.02
- DSGN 0.03
- Stochastic Oscillator
- CRNT 83.72
- DSGN 77.27
About CRNT Ceragon Networks Ltd.
Ceragon Networks Ltd is a wireless transport company in terms of unit shipments and wide distribution of its business, providing high-capacity wireless connectivity solutions to markets across various industries, mainly wireless (mobile) networks service providers. Geographically the company generates the key revenue from India. The company also has presence in North America, Europe, Africa, Asia-Pacific and Middle East, and Latin America. The company's products include IP-50 Platform, IP-20 Platform, Pointlink.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.